Cutler Group’s Ovid Therapeutics OVID Stock Holding History

Cutler Group’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$2K	–	5325
2020 Q3	$2K	Buy	+1,000	New	+$6.69K	﹤0.01%	4089

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cutler Group's OVID Position: Q1 2024 in Review

Cutler Group sold out of Ovid Therapeutics (OVID) in Q1 2024, closing a stake of 2,100 shares — an estimated $6K sold.

Cutler Group first reported a position in OVID in Q4 2020 and held it in 13 quarters. The position peaked at $8K in Q3 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q1 2024.

Cutler Group reported no remaining Ovid Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 2,100 Ovid Therapeutics shares in Q1 2024, an estimated $6K.
Cutler Group first reported a position in Ovid Therapeutics in Q4 2020 and held it in 13 quarters.
Cutler Group's Ovid Therapeutics position peaked at $8K in Q3 2023.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.